Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Voorraadrapport

Marktkapitalisatie: US$18.2m

Citius Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Citius Pharmaceuticals is Leonard Mazur, benoemd in Mar2016, heeft een ambtstermijn van 10.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.51M, bestaande uit 10.5% salaris en 89.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.51% van de aandelen van het bedrijf, ter waarde $ 276.11K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 10 jaar.

Belangrijke informatie

Leonard Mazur

Algemeen directeur

US$4.5m

Totale compensatie

Percentage CEO-salaris10.54%
Dienstverband CEO10.2yrs
Eigendom CEO1.5%
Management gemiddelde ambtstermijn5.3yrs
Gemiddelde ambtstermijn bestuur10yrs

Recente managementupdates

Recent updates

Analyseartikel • Apr 06

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 08

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Aug 01

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Apr 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Dec 25

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 28

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it had submitted a biologics license application (BLA) to the U.S. FDA for its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. According to CTXR, I/ONTAK (denileukin diftitox) is a purified and more bioactive formulation of previously FDA-approved therapy ONTAK. The BLA submission was supported by results from a phase 3 study. The submission comes after CTXR held a pre-BLA meeting with the FDA in July. The company in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. "The BLA filing for denileukin diftitox marks the first of our pipeline candidates to be submitted for FDA approval," CTXR CEO Leonard Mazur said in Wednesday's statement. Citius Pharmaceuticals (CTXR) stock -0.9% to $1.17 in premarket trading.
Seeking Alpha • Aug 11

Citius Pharmaceuticals GAAP EPS of -$0.06

Citius Pharmaceuticals press release (NASDAQ:CTXR): Q3 GAAP EPS of -$0.06. The company has reported $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023
Analyseartikel • Aug 05

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 12

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Tuesday said it had held a pre-biologics license application (BLA) meeting with the U.S. FDA to discuss its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. "Based on the FDA's pre-BLA meeting comments, we intend to move forward with our planned BLA submission for I/ONTAK in the second half of 2022," said CTXR CEO Leonard Mazur. The purpose of the pre-BLA meeting was to discuss the content and acceptability of the company's anticipated BLA for I/ONTAK. Citius (CTXR) in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. CTXR stock +1.3% to $0.92 in premarket trading.
Seeking Alpha • Jul 05

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated. Calculations show that Citius' current cash reserves of $55.8 million will only last the company until December 2022, just when it is expected to complete patient enrolment. There is a buy-out possibility after the company announced its intention to spin-off I/Ontak less than a year after license acquisition. Late-stage biopharmaceuticals company Citius Pharmaceuticals, Inc. (CTXR) informed investors that it had selected Biorasi to help it expand its Phase 3 Mino-Lok trial to clinical sites outside the U.S. Well, that formed one of the main highlights of Q2 2022, with investors yet to hear any news about patient enrolment almost 2 months after Biorasi's appointment. Still, there is a lot of excitement among investors with Citius expected to file its biologics license application ((BLA)) for I/ONTAK with the U.S. Food and Drug Administration ((FDA)) later in the second half of 2022. Thesis In this article, I will explain why I am raising my rating of CTXR to hold from sell. The plan to spin off I/Ontak as a standalone company appears to be a strategic move to spearhead growth and attract new investors to the company. As a pure-play oncology-focused biopharmaceutical project, the new company may leverage past mistakes that have delayed the release of topline data for Mino-Lok. Further, new acquisitions are in the offing, especially since the company's finances are inadequate to sustain the company for the next 12 months. Earlier Assessment In my previous article on CTXR, I expressed my concerns over the company's rush to buy E7777 where it burnt a significant amount of cash. Citius is yet to recover, and it is now on the verge of forming a new company to develop and commercialize I/Ontak. This decision comes as no surprise since it had already completed the Phase 3 trial in December 2021. Additionally, the pipeline development for the two main drug candidates: Mino-Lok and E7777 were on different trajectories. Apart from I/Ontak and Mino-Lok, Citius also has in its pipeline Halo-lido, Mino-Wrap, and a Stem cell platform. At the moment, the market is in a bear mode with investors eagerly waiting for some good news within the pipeline development to squeeze the shorts. For Citius, it has been a long time coming. In July 2021, CTXR announced a positive recommendation by the Independent Data Monitoring Committee ((IDMC)) to proceed with the planned Mino-Lok Phase 3 Trial. One year later, the company is yet to release test results. However, with the entry of Biorasi, we expect the company to fast-track patient enrolment. Overview of Patient enrolment and Phase 3 Trial Dynamics The total number of patients planned for Mino-Lok's phase 3 trial is 144, distributed as 1:1 to the standard of care ((SOC)) which is antibiotics. The objective of this trial (as noted in our earlier report) is to evaluate Mino-Lok's efficacy in salvaging colonized central venous catheters in patients with catheter-related or central line-associated bloodstream infection (CRBSI/ CLABSI). This evaluation is compared to the SOC of using antibiotics. In this trial, the protocol will be focused on reaching 92 catheter failure events that also correspond to the 144 patients. Albeit, the company is yet to disclose how many patients it has tested so far and how many events are in the balance. The primary endpoint is the time until catheter failure occurs, expressed in days from randomization into one of the two study arms. Simply put, this means that a patient with a catheter develops a bacterial infection, is subsequently assigned to one of the two study arms, and from then on, the time in days until the catheter needs to be replaced is noted. In the description of the study, this is given as a time frame of 6 weeks. To be able to show the statistical superiority of Mino-Lok over SOC, the time to catheter failure was defined as at least 38 days for Mino-Lok versus 21 days for SOC. The trial started in February 2018 and reached 40% enrollment in September 2019. The next 50% were reached in February 2020 and later 80% were reached in June 2021. This fits pretty nicely to a rate of 2% enrollment per month. It is interesting to note here that the normally increasing speed of enrollment throughout a study due to clinics being added and the slowdown of the study due to the COVID-19 pandemic have balanced each other out. However, there was a fundamental change by Q4 2021. Despite the increasing number of patients during the Covid19 pandemic, the company still expected a prolonged trial that would affect enrolment. This problem necessitated the recruitment of Biorasi. Citius CEO, Myron Holubiak was optimistic about the company's accomplishments in 2022, despite the apparent delays. He stated, As we move into 2022, we anticipate multiple positive milestones. These include accelerated enrollment and completion of the Mino-Lok trial during the year, topline results in the first half of 2022 for the recently completed I/ONTAK (E7777) Pivotal Phase 3 trial followed by a BLA submission in the second half of the year." Before this date, CTXR always said that topline data for Mino-Lok will be published in 2022, suddenly it changed and only completion of the trial (meaning full enrollment) is planned. Right now, there is no further update on the actual state of the enrollment. In February, CTXR again stated that trial completion will be reached in 2022 leaving open the final date for topline data. Enrollment must be higher than 80% but seems to be very slow. CTXR plans to reach full enrollment by the end of 2022. Now, with the help of Biorasi, this could be fastened up. But still, CTXR plans year-end 2022 for full enrollment and as long as we have no further update, we have to calculate with this. Questions are: What happened to the speed of the enrollment in H2 2021? Why was Biorasi asked for help so late? One could have added clinics in other countries also right from the beginning to keep the Phase 3 trial short. I have no idea why they waited so long for this step. Of special note is that the FDA does not require a certain number of patients but wants to see two adequate and well-designed clinical trials. With regards to Mino-Lok, the completed Phase 2 and the ongoing Phase 3 trials will be sufficient. The number of patients per trial strongly depends on the indication, the trial design and the statistical calculations planned and thus are different for every trial. The planned 144 patients in Phase 3 is enough for FDA approval if the results are good, and statistically significant to prove that Mino-Lok is safe. So what is remaining as far as Mino-Lok is concerned? In presenting its phase 3 topline data, Citius will first hold a Pre-NDA (New Drug Application) meeting with the FDA to talk about the NDA filing and if data are enough. It's the first check by FDA if there are enough data. Sometimes FDA demands additional trials, which can be small or even a full Phase 3 trial. Also, check with FDA if any designations will shorten the review process of the FDA from 10 to 6 months. Mino-Lok already was granted fast-track designation by the FDA meaning that their review process will be only 6 months. Writing the NDA application is a time-based process. It must contain all clinical, and pre-clinical data and manufacturing details. It is expected that it will take at least 6 months from filing to submission of data to the FDA (after the release of topline data). After filing the NDA, the FDA takes 2 months to approve or reject the data. After approval, the FDA needs another 6 months (with fast-track designation, otherwise it takes 10 months) to check the NDA and decide about the approval of Mino-Lok. Thus, in general, CTXR has to prepare everything about Mino-Lok including all results and data but also how it is manufactured and the corresponding documents that prove good manufacturing practice and quality control mechanisms, etc. This means that from topline data onward I believe CTXR will need at least 6 months until NDA submission, followed by a total of 8 months (2 months needed by the FDA to accept the filing and 6 months to review the NDA) until the FDA will finally decide if Mino-Lok is approved. This means with topline data in H1 2023, approval could be in mid-2024. Selling Halo-Lido? Investors are looking forward to CTXR's selling of Halo-Lido, especially after the Phase 2B trial. Whether it will be a possibility or not remains a subject under discussion. Still, the company desperately needs financial backup. Before we address the financial standpoint, we need to underscore the fact that the FDA is yet to approve a prescription drug for the treatment of hemorrhoids. Once approved, Halo-Lido could become the first drug to treat hemorrhoids in the US. Citius Chairman, Leonard Mazur confirmed that the company had received several interested buyers back in 2021. We can speculate that one of the buyers may be interested in buying out Citius but may not be interested in I/Ontak or E7777- the reason for the spin-off.
Seeking Alpha • Apr 13

Critical Care Biopharma - Citius Pharmaceuticals

Citius Pharmaceuticals is a late-stage biopharma focused on critical care products. Preventing shareholder dilution. Resumption of clinical trials after COVID-19.
Seeking Alpha • Mar 28

Citius: 2022 Is A Year Of Catalysts

5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10.
Analyseartikel • Dec 04

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 26

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius stock price reacted to no safety concerns identified by the DMC, to surge 102.86% (YoY) and +108.82% (YTD). Citius has prioritized E7777 threatening to derail the company's progression with Mino-Lok. Continual medical development may overthrow the use of CVCs due to the high mortality rate of 12%-25% associated with CLABSI. With a cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment of $40 million and milestone payments of up to $110 million.
Analyseartikel • Aug 28

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Citius...

Analyse CEO-vergoeding

Hoe is Leonard Mazur's beloning veranderd ten opzichte van Citius Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2026n/an/a

-US$46m

Dec 31 2025n/an/a

-US$36m

Sep 30 2025US$5mUS$475k

-US$37m

Jun 30 2025n/an/a

-US$41m

Mar 31 2025n/an/a

-US$43m

Dec 31 2024n/an/a

-US$41m

Sep 30 2024US$4mUS$475k

-US$40m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$39m

Sep 30 2023US$2mUS$475k

-US$34m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$28m

Sep 30 2022US$1mUS$400k

-US$34m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021n/an/a

-US$26m

Sep 30 2021US$788kUS$348k

-US$25m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020n/an/a

-US$21m

Sep 30 2020US$550kUS$250k

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019n/an/a

-US$16m

Sep 30 2019US$473kUS$250k

-US$16m

Compensatie versus markt: De totale vergoeding ($USD 4.51M ) Leonard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 630.36K ).

Compensatie versus inkomsten: De vergoeding van Leonard is gestegen terwijl het bedrijf verliesgevend is.

CEO

Leonard Mazur (80 yo)

10.2yrs
Tenure
US$4,507,940
Compensatie

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer and President of Citius Oncology, Inc. from August 12, 2024. He has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01, 2022...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Leonard Mazur
Co-Founder10.2yrsUS$4.51m1.51%
$ 276.1k
Myron Holubiak
Co-Founder & Executive Vice Chairman10.6yrsUS$2.51m0.29%
$ 53.6k
Myron Czuczman
Executive VP & Chief Medical Officer5.8yrsUS$2.46m0%
$ 0
Jaime Bartushak
Chief Business Officer & CFO8.5yrsUS$1.73m0.0089%
$ 1.6k
Gary Talarico
Executive Vice President of Operations10.2yrsgeen gegevensgeen gegevens
Ilanit Allen
Vice President of Investor Relations & Corporate Communicationsno datageen gegevensgeen gegevens
Alan Lader
Senior VP and Head of Clinical Operations & Quality Assurance4.3yrsgeen gegevensgeen gegevens
Dhananjay Wadekar
Senior Vice President of Business Strategy5.3yrsgeen gegevensgeen gegevens
Kelly Creighton
Executive Vice President of Chemistry4.5yrsgeen gegevensgeen gegevens
Nikolas Burlew
Executive Vice President of Quality Assurance3.3yrsgeen gegevensgeen gegevens
Catherine Kessler
Executive Vice President of Regulatory Affairs2.7yrsgeen gegevensgeen gegevens
5.3yrs
Gemiddelde duur
70.5yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van CTXR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Leonard Mazur
Co-Founder11.7yrsUS$4.51m1.51%
$ 276.1k
Myron Holubiak
Co-Founder & Executive Vice Chairman10.6yrsUS$2.51m0.29%
$ 53.6k
Dennis McGrath
Independent Director3.3yrsUS$716.71k0%
$ 0
Michael Matthay
ARDS Scientific Advisory Board Memberno datageen gegevensgeen gegevens
Suren Dutia
Independent Director10.6yrsUS$729.71k0%
$ 0
Carol Webb
Independent Director10.2yrsUS$707.39k0.0017%
$ 317.5
Eugene Holuka
Independent Director9.9yrsUS$710.71k0.00035%
$ 63.9
Issam Raad
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
Mark Rupp
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Leonard Mermel
Member of Scientific Advisory Board7.8yrsgeen gegevensgeen gegevens
John Laffey
ARDS Scientific Advisory Board Member4.9yrsgeen gegevensgeen gegevens
Lorraine Ware
ARDS Scientific Advisory Board Memberno datageen gegevensgeen gegevens
10.0yrs
Gemiddelde duur
78yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CTXR zijn ervaren en ervaren (gemiddelde ambtstermijn van 10 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/22 11:18
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/09/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Citius Pharmaceuticals, Inc. wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.
Jason McCarthyMaxim Group